A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Phase of Trial: Phase II
Latest Information Update: 20 Jun 2016
Price : $35 *
At a glance
- Drugs Rucaparib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RUCAPANC
- Sponsors Clovis Oncology
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Status changed from completed to discontinued as reported by results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2016 According to Clovis Oncology media release, final results of the RUCAPANC study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.